Goodbye Antibodies, Hello AlzAntibodies: New Database Is Growing on Alzforum
A collection of antibodies against microglial proteins is starting off a new database on Alzforum.
6458 RESULTS
Sort By:
A collection of antibodies against microglial proteins is starting off a new database on Alzforum.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
Plasma p-tau climbs as bears sleep. Post-torpor, tau reverts to normal. Does neuronal metabolic activity have to do with it?
Brain-derived forms of tau distinguished people with Alzheimer's from those with other neurodegenerative diseases.
Mirroring earlier results, a larger study finds that high levels of this tau fragment in CSF tracked with neurofibrillary tangles, but not amyloid plaques.
Antemortem plasma p-tau217 predicted the extent of amyloid plaques and neurofibrillary tangles seen postmortem.
In some patients, the blood Aβ42/40 test fell too close to the cutoff for specialists to confidently diagnose AD. Comorbidities, drugs also complicate results. Two CSF tests are FDA-approved.
CSF monocytes increasingly crank out the chemokine CXCL16, while T cells up its receptor, CXCR6. The same cross-talk unfolded among microglia and T cells around plaques.
The assay captures α-sheet structure. It detected AD with 99 percent accuracy, including among healthy people who later became cognitively impaired.
The more foliage near a person’s residence, the less likely they are to have either disease.
In a small pilot study, tailoring lifestyle changes to the individual boosted cognition, with an effect size three times that seen in the Finger trial.
In the Graduate trials, the anti-amyloid antibody gantenerumab cleared only half as much plaque as it had done in earlier studies. Is formulation or dosing to blame?
Conformers amplified from CSF of late-stage PD adopt distinct folds and trouble neurons.
In a head-to-head comparison, donanemab banished four times as much plaque in the first six months as aducanumab did, partly due to its faster titration.
ApoE2 was detected in cerebrospinal fluid of ApoE4 carriers with Alzheimer’s disease who received a virus expressing the protective allele.
No filters selected